

# **Factsheet**

full title Personalised blueprint of intestinal health

programme Horizon Europe / HORIZON-HLTH-2022-STAYHLTH-02

contract number 101095470

abstract miGut-Health aims to develop a personalised blueprint of intestinal health to predict and prevent inflammatory bowel disease (IBD). The overall goal is to deliver interdisciplinary solutions (molecular, nutritional, eHealth and patient engagement/empowerment level) for health promotion and disease prevention that would enable active patient engagement in health and self-care management.

> Taking on this mission, miGut-Health pursues the following strategic goals:

- To integrate state-of-the-art omics (molecular, clinical, nutrition, social and environmental) for identifying actionable biomarkers, risk and health-promoting factors linked to health-to-disease transition in the general population, IBD high-risk persons, and as IBD patients.
- To perform systems-level analyses of chronic inflammation by applying integrative models from omics and clinical data to predict risk for health-to-disease transition in IBD.
- To perform a proof-of-concept controlled clinical trial studying a nutrient elimination diet (here: gluten-free) and its impact on intestinal inflammation in IBD patients and high-risk individuals.
- To exploit the impact of microbiome-derived diet-associated metabolites on gut inflammation reversion and restoration of barrier integrity and function using an innovative co-culture system of primary human intestinal organoids and sorted immune cell subsets.
- To develop and apply novel technologies (sensors, mobile apps) to dynamically monitor individual nutrition as well as physical activity and principal health status.
- To implement a patient-centred approach for personalized health and self-care engagement targeted at IBD patients, individuals at risk for IBD and the general population, as well as tools for healthcare professionals.

Project funded by







duration 48 months (01/01/2023 – 31/12/2026)

project funding € 7,537,493.75 (€ 7,126,243.75 funded by the European Union plus € 411,250.00 funded by the State Secretariat for Education, Research, and Innovation – SERI as a financial contribution to the Swiss partner)

#### Belgium partners

The European Federation of Crohn's & Ulcerative Colitis Associations

### Denmark

Region Hovedstaden

# Germany

- University Hospital Schleswig Holstein
  - o Christian-Albrechts-University of Kiel (Affiliated entity)
- Medical Center Hamburg-Eppendorf (UKE)
- Eurice European Research and Project Office GmbH
  - RISE Research and Innovation Services (Affiliated entity, Croatia)

#### Israel

Weizmann Institute of Science

### Italy

Università Cattolica del Sacro Cuore

# Lithuania

Lithuanian University of Health Sciences

## Netherlands


University Medical Center Groningen

## Sweden

Örebro University

### Switzerland

École Polytechnique Fédérale de Lausanne









### **CONTACTS**

coordinator Prof. Andre Franke

University Hospital Schleswig-Holstein Email: a.franke@ikmb.uni-kiel.de

co-coordinator Prof. Jurgita Skieceviciene

Lithuanian University of Health Sciences Email: <a href="mailto:jurgita.skieceviciene@lsmuni.lt">jurgita.skieceviciene@lsmuni.lt</a>

project manager Antonija Zrno Culap

RISE – Research and Innovation Services

Email: a.zrno-culap@eurice.eu

website <a href="https://www.migut-health.eu">https://www.migut-health.eu</a>

social media X: <a href="https://twitter.com/miGutHealth">https://twitter.com/miGutHealth</a>

LinkedIn: <a href="https://twitter.com/miGutHealth">https://twitter.com/miGutHealth</a>



